Where We Are NowWe all wanted a big win with the Diabetes results. That eluded us - although I'm not sure a big win would have been in the cards no matter how it turned out. Basically, it was a very small study that I think was intended to postulate and test a theory around the lowered glucose measurements they had found in earlier trials.
The result here seems to be that the impact upon glucose readings is a longer-term thing - not a direct result of the drug but perhaps an indirect result. This is by no means not a negative thing if the findings regaridng MACE and glucose in SUSTAIN and ASSURE are repeated. This could significantly expand our target market and create a bigger revenue stream for 208. Which could save a lot of lives.
So where are we now?
We have a new CEO for Zenith. Sounds like a good thing, as she seems to have a strong background. Just what we need. Plus, the move was also a vote of confidence by the Board (and Dart I presume) in Don. Don's now Chairman with Peter J. being "lead Director." So everybody loves everybody. Which is usually a good sign when it comes to corporations.
Does this mean Zenith is being directed even more speedily to an IPO? That would nice if true....
Over at RVX, we continue with the experienced leadership of DMcC. I think that's also a good thing, as few people know anywhere near as much from a business standpoint about RVX than DMcC of course.
We have some news coming I hope regarding Alzheimer's. I personally wonder why it is taking so long. The longer it takes, the more concerned I get that we may not have won the funding prize. But we don't know yet.
We have details coming I'm sure about the upcoming reMACE trial. That should be interesting.
We'll know more soon, as I expect that we'll have a Webcast for each company soon.